A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

NCT06294613 | Recruiting

• 1 other identifier: CIV-23-07-043672
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 15 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker. Only one eye per subject can be enrolled.

Conditions

Vitreoretinal Disease

Outcome Measures

Primary Outcomes (1)

• Safety Outcome

  incidence and severity of investigational device-related (definitely or probably) adverse events, for all subjects treated with the study device (Safety Population).

  3 Months

Study Arms (1)

vitreoretinal surgery supported by Luca System

OTHER

Device: vitreoretinal surgery

Interventions

vitreoretinal surgery DEVICE

Patients undergoing vitreoretinal surgery

vitreoretinal surgery supported by Luca System

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Given written Informed Consent by subject,
• Males or females aged 18 - 85 years, pseudophakic or aphakic,
• Willing and able to comply with the schedule for follow-up visits,
• Requiring vitrectomy under general anesthesia (conditions include vitreous hemorrhage treatment (with potential clinical conditions including diabetic retinopathy, vascular occlusion, adverse effect of anticoagulant therapy), macular pucker),
• BCDVA \<7/10,
• Deemed fit for robotic surgery per surgeons' assessment, including ability to undergone general anesthesia,
• Beneficiary of health insurance.

You may not qualify if:

• Uncontrolled systemic disease that could increase the operative risk or confound the outcome (autoimmune disease, uncontrolled hypertension, lung and heart disease impairing respiratory function, or any other medical condition as deemed by the Clinical Investigator),
• BMI (kg/m²) \> 30,
• Axial length \<22 or \>26 mm per ocular biometry, inclusive,
• Presence of clinically significant ocular inflammation or infection within 30 days of Preop Visit, such as CME, uveitis, etc.,
• Ocular condition, that in the opinion of the Clinical Investigator, may predispose for future complications or confound visual acuity results, including profound amblyopia (\<1/10) or strabismus,
• Ocular condition presenting associated pathology likely to require additional surgical manipulation, such as known need for membrane peeling, or retinal neovacular formation to be cut,
• Already vitrectomized on the study eye,
• Presenting retinal detachment or retinal tear,
• History of ocular traumatism; post-traumatic vitreous hemorrhage,
• Corneal scar preventing clear visualization of fundus,
• Any associated ocular pathology or ocular degenerative disorder that is uncontrolled such as glaucoma with clinical visual defect or IOP not controlled by medical treatment, uveitis, optic nerve damage,
• Subjects without light perception,
• Subject participating in other clinical studies,
• Subject being dependent on the Sponsor or Clinical Investigator,
• Pregnant or lactating women, based on self-declaration.

Sponsors & Collaborators

• Acusurgical: lead

Study Sites (1)

UZ Gent

Ghent, East Flanders, 9000, Belgium

RECRUITING

MeSH Terms

Interventions

Vitreoretinal Surgery

Intervention Hierarchy (Ancestors)

Ophthalmologic Surgical Procedures; Surgical Procedures, Operative

Central Study Contacts

Charlene Braun

CONTACT

+33663334352; charlene.braun@acusurgical.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 28, 2024
• First Posted: March 5, 2024
• Study Start: February 8, 2024
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: January 30, 2025

Record last verified: 2024-02

Locations

BE (1)